goodrx novo nordisk - Search News

News

Novo Nordisk to sell weight-loss drug for $499

Fox Business on MSN · 3d

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

Reuters on MSN · 3d

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

The Pharma Letter · 2d

GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month.

3don MSN

GoodRx stock soars after striking deal to sell Novo Nordisk's GLP-1s for $499/month

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...

3don MSN

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

2d

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results